Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2081086 | 1.00 | CHRM2 (0.34) | CHRM2CHRM1CHRM3GPR119HCRTR2 | |
| SCHEMBL2081089 | 1.00 | CHRM2 (0.34) | CHRM2CHRM1CHRM3GPR119HCRTR2 | |
| SCHEMBL2079695 | 0.86 | — | — | |
| SCHEMBL2079697 | 0.86 | — | — | |
| SCHEMBL2079700 | 0.86 | — | — | |
| SCHEMBL2080702 | 0.81 | CHRM2 (0.42) | CHRM2CHRM1CHRM3NR1H2 | |
| SCHEMBL15836693 | 0.80 | GPR119 (0.40) | CHRM2CHRM1CHRM3GPR119HCRTR2 | |
| SCHEMBL2078656 | 0.80 | ATM (0.34) | GPR119HCRTR2 | |
| SCHEMBL2078658 | 0.80 | ATM (0.34) | GPR119HCRTR2 | |
| SCHEMBL2078653 | 0.80 | ATM (0.34) | GPR119HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906532-B2 | Antiserotonine agents; gastrointestinal disorders; irritable bowel syndrome; central nervous system disorders; Alzheimer's disease; cognition activators; analgesics; cardiovascular disorders; antidiabetic agents; sleep disorders | PFIZER INC. (US) | 2011-03-15 | — | — | US | disclosed |
| EP-1910340-B1 | INDAZOLECARBOXAMIDE DERIVATIVES AS 5HT4 RECEPTOR AGONISTS | PFIZER (US) | 2009-11-18 | — | — | EP | disclosed |
| US-20080269211-A1 | Indazole Derivatives | PFIZER INC | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269211-A1 | Indazole Derivatives | GPR119, HRH4, HTR4 | CHRM2 14/4885CHRM1 8/4885CHRM3 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.